NCT02043678 2025-02-19
ERA 223
Bayer
Phase 3 Completed
Clinical Trials
19 trialsNCT03315260 2024-02-08
Treatment Satisfaction With Ra-223 in Japan
Bayer
Completed
NCT04256993 2024-01-16
PRECISE
Bayer
Completed
NCT00337155 2023-11-02
BAY88-8223, Dose Finding Study in Patients With HRPC
Bayer
Phase 2 Completed
NCT04681144 2023-10-26
QOLRAD
Bayer
Completed
NCT03419442 2020-10-22
Multi-academic Center Study of Xofigo Patients
Bayer
Completed
NCT02034552 2019-07-23
A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
Bayer
Phase 2 Completed
NCT02023697 2019-07-12
Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone
Bayer
Phase 2 Completed
NCT03325127 2018-10-31
Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study
Bayer
Withdrawn
NCT01810770 2018-09-19
Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis
Bayer
Phase 3 Completed
NCT02518698 2018-09-18
Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population
Bayer
Completed
NCT01929655 2018-04-24
Japanese BAY88-8223 Monotherapy Phase II Study
Bayer
Phase 2 Completed
NCT01934790 2018-03-26
Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases
Bayer
Phase 1/2 Completed
NCT02729103 2018-01-25
Treatment Patterns in Metastatic Prostate Cancer
Bayer
Completed
NCT01565746 2016-10-17
Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients
Bayer
Phase 1 Completed
NCT00667537 2015-12-14
PK in Pts With HRPC & Skeletal Metastes
Bayer
Phase 1 Completed
NCT01516762 2014-07-14
Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
Bayer
No longer available
NCT00459654 2014-06-25
A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer
Bayer
Phase 2 Completed
NCT00748046 2014-06-25
Alpharadinâ„¢ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton
Bayer
Phase 1 Completed